

NAME: Professor John Vincent Reynolds, *MA, MB, BCh, MCh, FRCSI*.

CURRENT POSITION:

- Professor of Surgery and Head of Department, Trinity College Dublin (since July 2001)
- National Director for Upper GI Cancer Services, Ireland
- Regional director of cancer services in the south-west area of the Eastern Regional Health Authority
- Principal Investigator, Dublin Molecular Medicine Centre
- Scientific Director, Cancer Clinical Trials Consortium, ICORG
- Associate Editor, Digestive Surgery
- Chairperson of the Irish Society for Clinical Nutrition and Metabolism (IRSPEN).

PREVIOUS APPOINTMENTS:

1996-2001: Consultant Surgeon and Senior Lecturer, St. James's Hospital, Dublin
1994-1996: Consultant Surgeon and Senior Lecturer, St. James's University Hospital and the University of Leeds
Clinical and research training involved periods at the University of Pennsylvania, Philadelphia, the Memorial Sloan-Kettering Cancer Centre in New York, and St. Mary's Hospital, London.

ACADEMIC AND PROFESSIONAL QUALIFICATIONS:

1981: MB, BCh, University College Dublin

1985: FRCSI

1990: MCh

HONOURS & AWARDS:

Final MB BCh 2nd Class Honors Degree (1st Place in Surgery)

Presidents Research Award, Association for Academic Surgery, 1987

Presidents Prize, Royal Academy of Medicine in Ireland, 1990

The Augustine Mehigan Award for Teaching Excellence, 1992

The Sylvester O'Halloran Scholarship, 1992

The Gussy Mehigan Memorial Scholarship, 1993

International Fellowship in Surgical Oncology, 1993-1994

Harry M. Vars Award for Nutrition Research, ASPEN, 1997

TOTAL RESEARCH FUNDING : €5,400,000

Active Grants and Scholarships in Department of Surgery

Health Research Board Post-Doctoral Fellowship 2009-2012. Dr. J Lysaght. Investigating the immunomodulatory effects of adipose tissue in oesophageal and colorectal cancer. €205,885.

Cancer Research Ireland 2009-2012. Dr. Claire O'Donohue.

Health Research Board Clinical Fellowship 2010-2013. Dr. Sam Lynch. Scientific sponsor: Dr. Graham Pidgeon. COX2, thromboxane synthase and prostacyclin synthase signalling pathways in oesophageal cancer. €195,249 (overhead contribution=58,578).

Cancer Research Ireland 2010-2013. Dr. Stephen Maher.

Cancer Research Ireland 2010-2013. Dr. Sarah Picardo.

Science Foundation Ireland, RFP. 2011-2015. The role of random mitochondrial mutations during disease progression in Barrett's Oesophagus. €216,840.

Health Research Board. 2011-2014. Influence of the tissue microenvironment on the activity of dendritic cells during disease progression in Barrett's Oesophagus patients; identification of novel therapeutic targets. €239,490.

Health Research Board 2011-2013. The role of microRNA and random mitochondrial DNA mutations in a novel clinically-relevant isogenic model of radioresistance in oesophageal adenocarcinoma. €183,000.

Health Research Board 2011-2014. Investigating the role of T cells in adipose tissue and hepatic inflammation in obesity associated cancer. €270,279.

Health Research Board Clinical Fellowship 2011-2014. A. Mongan. Mechanisms linking obesity, genomic instability and radioresistance. €220,371.

Cancer Research Ireland Fellowship. 2011-2014. Dr Mary Clare Cathcart. Examination of the role of thromboxane synthase signaling and its link to tumour angiogenesis in colorectal cancer. €162,805.

Science Foundation Ireland/Technology Innovation Development Award. 2012-2013. PI. J. O'Sullivan. Validation of novel anti-angiogenic drugs using *ex vivo* and *in vivo* colorectal cancer models. €93,058.

Oesophageal Cancer Fund: 2011-2014; Establishment of Barrett's Registry and Bioresource. €485,000.

BOOK CHAPTERS, EDITORIALS AND REVIEWS

1. **Reynolds JV**, Mies C , Daly JM. Mesenchymal Infiltrating Tumours. In: *The Breast: Comprehensive Management of Benign and Malignant Diseases*. Bland KI, Copeland III EM (editors). WB Saunders, Philadelphia 1990; pp 220-221.
2. **Reynolds JV**, Sommers SS, Guillou PJ. Immunosuppressive effects of surgery: Therapeutic application of cytokines. *Interferons and Cytokines* 1990; 14: 16-18.
3. **Reynolds JV**, MacDermott EWM, O'Higgins NJ. Primary chemotherapy in early breast cancer. *Journal of the Irish College of Physicians and Surgeons*. 1992, 21: 126-128.
4. **Reynolds JV**, Hyland JM. Obstructing the flow: A role for growth hormone in surgical patients. *Journal of the Irish College of Physicians and Surgeons*, 1994. 23: 29-32.
5. **Reynolds JV**. Cytokines: Applications in colorectal cancer. *Colonews*, 1995, 4: 1-5.
6. **Reynolds JV**. Current perspectives on adjuvant therapy for resectable rectal cancer. *Journal of the Irish College of Physicians and Surgeons*, 1995 ; 24: 185-91
7. Windsor ACW, Sommers SS, Guillou PJ, **Reynolds JV**. Potential for local and systemic manipulation of the immune response in the prevention of perioperative sepsis. *British Journal of Surgery*, 1995; **82**: 1460-67.
8. **Reynolds JV**, Murchan P, Keane FBV, Tanner WA. Infection and sepsis in obstructive jaundice. *Journal of the Irish College of Physicians and Surgeons*, 1997; 24: 12-18.
9. **Reynolds JV**, Guillou PJ. Immunology in general surgery. *Current Practice in Surgery* 1995; **7**: 149-56.
10. **Reynolds JV**. Gut barrier function in the surgical patient *British Journal of Surgery* 1996; **83**: 1668-9.
11. Kanwar S, Windsor ACW, **Reynolds JV**. Early enteral nutrition in acute pancreatitis *Nutrition* 1999; **15**: 951-2.
12. **Reynolds JV** Enteral nutrition in acute pancreatitis *In:Pancreatic Disease. Towards the Year 2000*. Imrie CW, Johnson C (eds). Springer-Verlag 1998 pp 134 – 140.
13. **Reynolds JV**. Barrett's oesophagus, intestinal metaplasia and adenocarcinoma. *In: Management of Upper Gastrointestinal Cancer* Daly JM, Hennessy TPJ, Reynolds JV (eds): WB Saunders (London) 1999. pp 36-57.
14. Welsh FKS, **Reynolds JV**. Gut Barrier Failure. *In "Sepsis and Multiorgan Dysfunction"*. Eds, Deitch Ed, Windsor ACJW. Harcourt Brace.

ORIGINAL MANUSCRIPTS

1. **Reynolds JV**, O'Sullivan GC, Keely M. Multiple pulmonary leiomyomatous hamartomas. *Irish Medical Journal* 1984; 77: 106-7.
2. **Reynolds JV**, Zhang S, Thom AK, Ziegler MM, Naji A, Daly JM. Arginine as an immunomodulator. *Surgical Forum* 1987; 38: 415-8.
3. **Reynolds JV**, Zhang S, Thom AK, Ziegler MM, Naji A, Daly JM. Arginine, protein calorie malnutrition and cancer. *Journal of Surgical Research* 1988; 45: 513-22.
4. **Reynolds JV**, Zhang S, Ziegler MM, Daly JM. Immunomodulatory mechanisms of arginine. *Surgery* 1988; 106: 142-51.
5. Daly JM, **Reynolds JV**, Kinsley L, Dietiech-Gallagher M. Immune and metabolic effects of arginine in the surgical patient. *Annals of Surgery* 1988; 208: 512-8.
6. Sigal RK, **Reynolds JV**, Markmann JF, Shou J, Evantash E, Ziegler MM, Naji A, Daly JM. Upregulation of MHC Class 1: Effect on growth and LAK sensitivity of neuroblastoma. *Surgical Forum* 1988; 39: 572-5.
7. Choi H, **Reynolds JV**, Ziegler MM. Systematic analysis of the immunoregulation of a murine neuroblastoma. *Journal of Paediatric Surgery* 1989; 24: 15-20.
8. **Reynolds JV**, Choi H, Ziegler MM, Daly JM. The influence of natural killer cells in neuroblastoma. *Archives of Surgery* 1989; 124: 235-9.
9. Sigal RK, **Reynolds JV**, Lieberman M, Shou J, Daly JM. Helper T-cell depletion augments cytotoxicity to neuroblastoma. *Surgical Forum* 1989; 40: 550-3.
10. Shou J, **Reynolds JV**, Sigal RK, Daly JM. Growth hormone: immune and metabolic effects in tumour-bearing mice. *Journal of Surgical Research* 1989; 47: 442-50.
11. **Reynolds JV**, Ueno N, Steigman C, Johnston Jr. RB, Daly JM. Differential sensitivity of macrophages and T-cells to protein malnutrition. *Surgical Forum* 1989; 40: 99-102.
12. Lieberman M, Sigal R, Birch G, Shou J, **Reynolds JV**, Daly JM. Nutrient substrate potentiation of interleukin-2 immunotherapy. *Surgical Forum* 1990; 41: 5-7.
13. **Reynolds JV**, Shou J, Daly JM. The effects of dietary supplementation with the amino acid arginine on immune function in tumour-bearing and non tumour-bearing hosts. *Annals of Surgery* 1990; 211: 202-210.
14. Lieberman M, **Reynolds JV**, Goldfine J, Daly JM. Protein malnutrition inhibits antitumour responses to interleukin-2 immunotherapy. *Surgery* 1990; 108: 452-9.
15. Sigal RK, Lieberman M, **Reynolds JV**, Markmann J, Daly JM. Tumour immunization: improved results after vaccine modified with gamma interferon. *Arch. Surgery* 1990; 125: 308-12.

ORIGINAL MANUSCRIPTS

16. **Reynolds JV**, Shou J, Sigal RK, Ziegler MM, Daly JM. The influence of protein malnutrition on T-cell, natural killer cell, and lymphokine- activated killer cell function, and on biological responses to high-dose interleukin-2. *Cellular Immunology* 1990; 128: 569-77.
17. Daly JM, **Reynolds JV**, Sigal RK , Lieberman MD. Effect of dietary protein and amino acids on immune function. *Critical Care Medicine* 1990; 211: 202-10.
18. Sigal RK, Lieberman MD, **Reynolds JV**, Shou J, Ziegler MM, Daly JM. Low-dose interferon gamma renders neuroblastoma more susceptible to interleukin-2 immunotherapy. *Journal of Paediatric Surgery* 1991; 26: 395-6.
19. Lieberman MD, **Reynolds JV**, Redmond HP, Leon P, Shou J, Daly JM. Comparison of the effects of acute and chronic protein-energy malnutrition on host anti-tumour immune mechanisms. *Journal of Parenteral Enteral Nutrition* 1991; 15: 15-21.
20. **Reynolds JV**, Galloway J. Primary aortoduodenal fistula: A case report and review of the literature. *Irish Journal of Medical Science* 1991; 160: 381-4.
21. Redmond HP, Leon P, Lieberman MD, Shou J, **Reynolds JV**, Johnston Jr. RB, Daly JM. Impaired macrophage function in severe protein energy malnutrition. *Archives of Surgery* 1991; 126: 192-6.
22. **Reynolds JV**, Redmond HP, Ueno N, Steigman C, Ziegler MM, Daly JM, Johnston Jr. RB. Impairment of macrophage activation by protein malnutrition. *Cellular Immunology* 1992; 139: 493-504.
23. Somers SS, **Reynolds JV**, Guillou PJ. Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma. *Clinical Oncology* 1992; 4: 135-6.
24. **Reynolds JV**, Sweeney PS, Nolan N, Duffy MJ, McDermott EWM, O'Higgins NJ. Management of ductal carcinoma in situ of the breast. *Irish Journal of Medical Science* 1993; 162: 45-8.
25. **Reynolds JV**, Somers SS, Guillou PJ. Serum-mediated suppression of LAK cell generation in patients with metastatic gastrointestinal cancer. *Surgical Oncology* 1993. 2: 227-234.
26. **Reynolds JV**, Mercer P, McDermott EWM, Cross S, Stokes M, Murphy D, O'Higgins NJ. Audit of complete axillary dissection in breast cancer *European Journal of Cancer* 1994; 30(2): 148-149
27. Fulton GJ, O'Donoghue MK, **Reynolds JV**, Keane FBV, Tanner WA. Wedge resection alone or combined with phenolization for the treatment of ingrowing toenail. *British Journal of Surgery* 1994; 81: 1074-75.

ORIGINAL MANUSCRIPTS

28. **Reynolds JV**, Murchan P, Leonard N, Redmond HP, Hill A, Keane FBV, Tanner WA. Failure of macrophage activation in experimental obstructive jaundice: association with bacterial translocation. *British Journal of Surgery* 1995, 82: 534-538
29. **Reynolds JV**, Murchan P, Leonard N, Gough DB, Clarke P, Keane FBV, Tanner WA. High-dose interleukin-2 promotes bacterial translocation from the gut. *British Journal of Cancer* 1995, 72: 634-636.
30. **Reynolds JV**, Enker WE. A simple safe technique for stapled reconstruction following colonic resection. *Journal of the American College of Surgeons*. 1995, 181: 178-81
31. **Reynolds JV**, Walsh K, Goggin M, Ruigrok J, Hyland JM. Randomised comparison of silicone vs teflon cannulas for peripheral intravenous nutrition. *Annals of the Royal College of Surgeons* 1995; 77: 447-9.
32. Harbison J, **Reynolds JV**, Gibney R, Sheahan K, Hyland JM. Evidence for the polyp-cancer sequence in gallbladder cancer. *Irish Medical Journal* , 1997; **90**: 98.
33. **Reynolds JV**, Murchan P, Leonard N, Keane FBV, Tanner WA. Gut barrier failure in experimental obstructive jaundice. *Journal of Surgical Research* 1996; **62**: 11-16
34. Windsor ACW, Li A, Sommers SS, Guillou PJ, Sadek S, **Reynolds JV**. Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. *Surgical Oncology* 1995; 4: 277-9
35. **Reynolds JV**, Joyce WP, Nolan N, Sheahan K, Hyland JM. Pathological evidence in support of total mesorectal excision in the management of rectal cancer. *British Journal of Surgery* 1996; **83**: 1112-5.
36. **Reynolds JV**, O'Farrelly C, Leonard N, Murchan P, Fulton K, O'Morain C, Feighery C, Keane FBV, Tanner WA. Impaired gut barrier function in malnourished surgical patients. *British Journal of Surgery* 1996; **83**: 1288-92.
37. Welsh FKS, Farmery SM, Ramsden CW, Guillou PJ, **Reynolds JV**. Reversible defect in monocyte major histocompatibility complex class II expression in malnourished surgical patients. *Journal of Parenteral and Enteral Nutrition* 1996; **20**: 344-8.
38. **Reynolds JV**, Kanwar S, Welsh FKS, Windsor ACJ, Barclay GR, Guillou PJ. Does the route of feeding modify gut barrier function and clinical outcome in patients after major upper gastrointestinal surgery? 1997 Harry M. Vars Research Award. *Journal of Parenteral and Enteral Nutrition* 1997; **21**: 196-201
39. Klava A, Windsor A, Boylston AW, **Reynolds JV**, Ramsden CW, Guillou PJ Monocyte activation after open and laparoscopic surgery. *British Journal of Surgery* 1997; **84**: 1152-6.

ORIGINAL MANUSCRIPTS

40. Klava A, Winsor AC, Farmery SM, Woodhouse LF, **Reynolds JV**, Ramsden CW, Boylston AW, Guillou PJ. Interleukin-10. A role in the development of postoperative immunosuppression. *Archives of Surgery* 1997; 132: 425 – 9.
41. Blakeborough A, Mc Williams RG, Raja U, Robinson PJ, **Reynolds JV**, Chapman A. Pseudolipoma of inverted Meckels diverticulum: clinical, radiological and pathological correlation. *Eur Rad* 1997; 7: 900-4.
42. Welsh FKS, Ramsden CW, Mac Lennan K, Farmery S, Sheridan M, Guillou PJ, **Reynolds JV**. Increased intestinal permeability and altered mucosal immunity in jaundiced patients. *Annals of Surgery*, 1998; 227: 205 – 12
43. Welsh FKS, Kanwar S, Farmery S, Guillou PJ, **Reynolds JV**. Gut barrier function in malnourished patients. *Gut* , 1998; 42: 396 – 401
44. Windsor ACJ, Kanwar S, Li AG, Barnes E, Welsh F, Guillou PJ, **Reynolds JV**. Compared with parenteral nutrition, enteral feeding attenuates the acute phase response and improves disease severity in acute pancreatitis. *Gut*, 1998; 42: 431 – 435.
45. Kanwar S, Windsor A, **Reynolds JV** Early enteral nutrition in acute pancreatitis. *Nutrition*. 1999 Nov-Dec;15(11-12):951-2
46. White B, McHale J, Ravi N, **Reynolds J**, Stephens R, Moriarty J, Smith OP. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. *Br J Haematology* 1999; 107: 677-8
47. Kanwar S, Welsh FKS, Windsor ACW, Guillou PJ, **Reynolds JV**. Lack of correlation between failure of gut barrier function and septic complications following major upper gastrointestinal surgery. *Annals of Surgery* 2000; 23 (1): 88-95
48. Carton E, Caldwell M, Rana D, Tanner WA, Mc Donald G, **Reynolds JV**. Specialised intestinal metaplasia: prevalence and relationship to gastro-oesophageal reflux. *Br J Surg* 2000; 87: 116-121.
49. Mulligan ED, Purcell T, Lawlor P, **Reynolds JV**, Byrne PJ. Symptoms are a poor indication of severity of reflux in Barrett's oesophagus. *Br J Surg*. 2000 Mar;87(3):362-73.
50. Carton E, Mulligan ED, Keeling PW, Tanner A, McDonald G, **Reynolds JV**. Specialized intestinal metaplasia: analysis of prevalence, risk factors and association with gastro-oesophageal reflux disease. *Br J Surg*. 2000 Mar;87(3):362-73.#
51. Sweeney KJ, Rowe I, Lawlor P, Byrne P, **Reynolds JV**. The isolated hypertensive lower oesophageal sphincter: audit in a specialist unit. *Ir Med J*. 2000 Nov;93(8):232-4.

ORIGINAL MANUSCRIPTS

52. Lawlor PM, McCullough JA, Byrne PJ, **Reynolds JV**. Electrogastrography: a non-invasive measurement of gastric function. *Ir J Med Sci*. 2001 Apr-Jun;170(2):126-31.
53. Dunne B, **Reynolds JV**, Mulligan E, Kelly A, Griffin M. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. *J Clin Pathol*. 2001 Nov;54(11):841-5.
54. Ryan BM, McManus R, Daly JS, Carton E, Keeling PW, **Reynolds JV**, Kelleher D. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. *Br J Cancer*. 2001 Nov 16;85(10):1499-503.
55. Raouf A, Evoy D, Carton E, Mulligan E, Griffin M, Sweeney E, **Reynolds JV** Spontaneous and inducible apoptosis in oesophageal adenocarcinoma. *Br J Cancer*. 2001 Nov 30;85(11):1781-6.
56. McGrath JP, Browne M, Riordan C, Ravi N, **Reynolds JV** Expandable metal stents in the palliation of malignant dysphagia and oesophageal- respiratory fistulae. *Ir Med J*. 2001 Oct;94(9):270-2.
57. Sweeney KJ, Evoy D, Sultan S, Coates C, Moore DJ, Shanik DG, Kell MR, **Reynolds JV**. Endovascular approach to abdominal aortic aneurysms limits the postoperative systemic immune response. *Eur J Vasc Endovasc Surg*. 2002 Apr;23(4):303-8.
58. Mahmood Z, McMahon BP, Arfin Q, Byrne PJ, **Reynolds JV**, Murphy EM, Weir DG. Endocinch therapy for gastro-oesophageal reflux disease: a one year prospective follow up. *Gut*. 2003 Jan;52(1):34-9.
59. Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, **Reynolds JV**. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. *Dis Esophagus*. 2003;16(1):17-23.
60. Sweeney KJ, Kell MR, Coates C, Murphy T, **Reynolds JV**. Serum antigen(s) drive the proinflammatory T cell response in acute pancreatitis. *Br J Surg*. 2003 Mar;90(3):313-9.
61. Connolly EM, Gaffney E, **Reynolds JV**. Gastrointestinal stromal tumours. *Br J Surg*. 2003 Oct;90(10):1178-86.
62. Byrne PJ, Mulligan ED, O'Riordan J, Keeling PW, **Reynolds JV** Impaired visceral sensitivity to acid reflux in patients with Barrett's esophagus. The role of esophageal motility*. *Dis Esophagus*. 2003;16(3):199-203.

ORIGINAL MANUSCRIPTS

63. McCullough JA, Evoy D, Sweeney KJ, Meyers C, Ravi N, Keeling N, Byrne PJ, Reynolds JV. D2 lymphadenectomy in the management of gastric cancer. *Ir J Med Sci*. 2003 Jul-Sep;172(3):132-5.
64. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, **Reynolds JV**. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. *Ann Surg*. 2004 Apr;239(4):491-500.
65. Mulligan ED, Dunne B, Griffin M, Keeling N, **Reynolds JV** Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. *Eur J Surg Oncol*. 2004 Apr;30(3):313-7.
66. O'Riordan JM, Tucker ON, Byrne PJ, McDonald GS, Ravi N, Keeling PW, **Reynolds JV**. Factors influencing the development of Barrett's epithelium in the esophageal remnant postesophagectomy. *Am J Gastroenterol*. 2004 Feb;99(2):205-11.
67. Lawlor PM, McCullough JA, Byrne PJ, **Reynolds JV**. Gastric myoelectrical activity post-chemoradiotherapy and esophagectomy: a prospective study using subscapular surface recording. *Dis Esophagus*. 2004;17(1):76-80.
68. O'Riordan JM, Byrne PJ, Ravi N, Keeling PW, **Reynolds JV** Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. *Am J Surg*. 2004 Jul;188(1):27-33.
69. Sweeney K, Kell M, Ravi N, **Reynolds JV**. Major upper gastrointestinal surgery is associated with an early and sustained antigen-dependent pro-inflammatory T cell response. *Br J Surg* 2005; 92: 989-995.
70. Holland J, Hughes N, Carey M, Sweeney K, Byrne P, Ravi N, **Reynolds JV** Association of intraoperative splanchnic hypoperfusion with heightened acute phase response, increased intestinal permeability, and downregulation of monocyte function. *Am J Surg* 2005; 190: 393-400.
71. O'Riordan J, Abdel-Laetif M, Ravi N, Keeling N, Kelleher D, **Reynolds JV** Pro-inflammatory cytokine and nuclear kappa B expression along the metaplasia-dysplasia and adenocarcinoma sequence in the oesophagus. *Am J Gastroenterology* 2005 ; 100: 1257-64.
72. Abdel-Laetif MMM, O'Riordan JM, Ravi N, Kelleher D, **Reynolds JV**. Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy. *Dis Esophagus*, 2005; 18: 246-52.
73. Ravi N, Al-Sarraf N, Moran T, O'Riordan J, Rowley S, Byrne PJ, **Reynolds JV**. Acid normalization and improved esophageal motility after Nissen fundoplication: equivalent outcomes in patients with normal and ineffective esophageal motility. *Am J Surg* 2005; 190: 445-50.

ORIGINAL MANUSCRIPTS

74. Duggan S, Gallagher W, Fox E, Abdel-Laetif M, **Reynolds J**, Kelleher D. Low pH induces co-ordinate regulation of gene expression in oesophageal cells. *Carcinogenesis* 2006; 27: 319-27.
75. Jabbar A, Reynolds JV, Plunkett PK. Stab to second intercostals space: a bubbling extrapleural wound. *Emerg Med J* 2005; 22: 916-8.
76. Smith FM, **Reynolds JV**, Kay EW, Crotty P, Murphy JO, Hollywood D, Gaffney EF, Stephens RB, Kennedy MJ. Cox-2 overexpression in pre-treatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. *Int J Radiat Oncol Biol Phys* 2005; 3.
77. Abdel-Laetif MM, Rauof A, Sabra K, Kelleher D, **Reynolds JV**. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. *J Chemotherapy* 2005; 17: 539-49.
78. Smith FM, **Reynolds JV**, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. *Eur J Surg Oncol* 2006; 32: 55-64.
79. Ravi N, Stuart RC, Byrne PJ, **Reynolds JV**. Effect of physical exercise on esophageal motility in patients with esophageal disease. *Dis Esophagus* 2005; 18: 374-7.
80. Ryan AE, Rowley S, **Reynolds JV**. Adenocarcinoma of the oesophagus and gastric cardia: Male preponderance in association with obesity. *Eur J Cancer* 2006; 42: 1151-8.
81. Ryan AE, Ravi N, Byrne P, **Reynolds JV**. Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit. *Clin Nutrition* 2006; 25: 386-93
82. Pritchard R, Ravi N, Byrne P, **Reynolds JV**. Management of spontaneous perforation of the oesophagus (Boerhaaves syndrome). *Ir J Med Sci* 2006, 175: 66-70.
83. Malik V, Keogan M, Gilham, Duffy G, Ravi N, Reynolds JV. FDG-PET scanning in the management of cancer of the oesophagus and oesophago-gastric junction: Early experience with 100 consecutive cases. *Irish J of Medical Science* 2006; 175: 48-54.
84. McGuill M, Ravi N, Byrne P, **Reynolds JV**. Clinicopathological factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. *Dis Esophagus* 2006, 19: 273-6.
85. Mahmood N, Byren PJ, Mc Mahon BP, Murphy EM, Arfin Q, Ravi N, Weir D, P, **Reynolds JV**. Comparison of transesophageal endoscopic fundoplication (TEP) with laparoscopic Nissen fundoplication in the treatment of uncomplicated reflux disease. *Am J Gastroenterology* 2006; 101: 431-6.

ORIGINAL MANUSCRIPTS

86. **Reynolds JV**, Ravi N, Moore J, Byrne P. Prospective evaluation of quality of life in patients undergoing multimodality therapy or surgery alone for oesophageal cancer. *Br J Surg* 2006, 19: 273-6.
87. Abdel-Laetif MM, Windle H, Terres A, Eidhin DN, Kelleher D, **Reynolds JV**. Helicobacter pylori extract induces nuclear factor kappa B, activator protein-1, and cyclooxygenase-2 in esophageal epithelial cells. *J Gastrointest Surg* 2006; 101: 431-6.
88. Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, Mc Guigan J, **Reynolds JV**, Murray LJ. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-dysplasia sequence. *Cancer Res* 2006; 66: 4975-82.
89. Byrne PJ, Power C, Lawlor P, Ravi N, **Reynolds JV**. Laryngopharyngeal reflux in patients with symptoms of gastroesophageal reflux disease. *Dis Esophagus* 2006; 19: 377-81
90. **Reynolds JV**, Ravi N, Hollywood D, Kennedy MJ, Rowley S, Ryan A, Hughes N, Carey M, Byrne P. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. *J Thorac Cardiovasc Surgery*. 2006; 132: 549-55
91. Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Rauof AA, O'Byrne K, Hollywood D, Muldoon C, **Reynolds JV**. ¹⁸F FDG Uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. *Br J Cancer*, 2006; 95: 1174-9
92. MacGuill M, Mulligan E, Ravi N, Srowley S, Byrne PJ, Hollywood D, Kennedy J, Keeling PN, **Reynolds JV**. Clinicopathologic features predicting response or resistance to neoadjuvant chemoradiotherapy in esophageal cancer. *Dis Esophagus*. 2006; 132: 549- 55.
93. Smith FM, Gallagher W, Fox E, Stephens RB, Petricoin EF, Liotta LA, Kennedy MJ, **Reynolds JV**. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal therapy. *Ann Surg* , 2007. 245: 259-266
94. Mc Gill M, **Reynolds JV**. Isolated tumour cells in pathological lymph node-negative lymph nodes adversely affect prognosis in cancer of the oesophagus or oesophago-gastric junction. *J Clin Pathol* 2007 (in press; PMID 17220206)
95. Murphy SJ, Hughes AE, Patterson CC, Anderson LA, Watson RG, Johnston BT, Comber H, Mc Guigan J, **Reynolds JV**, Murray L.. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma. *Carcinogenesis* 2007 Jun 28 (6):1323-8.

ORIGINAL MANUSCRIPTS

96. Gillham C, **Reynolds J**, Hollywood D. Predicting the response of localised oesophageal cancer to neoadjuvant chemoradiation. *Worl J Surg Oncol* 2007; 5: 97-102.
97. **Reynolds JV**, Muldoon C, Hollywood D, Ravi N, Rowley S, O' Byrne K, Kennedy J, Murphy T. Long-term outcomes following multimodal therapy for esophageal cancer. *Ann Surg* 2007; 245: 707-16
98. Johnson C, Tuite D, Pritchard R, **Reynolds J**, Mc Eniff N, Ryan JM. Use of provocative angiography to localize site in recurrent gastrointestinal bleeding. *Cardiovasc Intervent Radiol* 2007; 30: 1042-6.
99. Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, **Reynolds JV**, Murray L. Risk factors for oesophageal adenocarcinoma; results from the FINBAR study. *World J Gastroenterol* 2007; 13: 1585-94.
100. Anderson LA, Murphy SJ, Johnston BT, Watson P, Ferguson H, Bamford KB, Ghazy A, Mc Carron P, Mc Guigan J, **Reynolds JV**, Murray LJ. Relationship between Helicobacter pylori infection and gastric atrophy, oesophageal inflammation, maetaplasia, adenocarcinoma sequence: results of the FINBAR study. *Gut* 2007: PMID 18025067
101. Healy LA, Ryan AM, Gopinath B, Rowley S, Byrne PJ, **Reynolds JV**. Impact of obesity on outcomes in the management of localized adenocarcinoma of the esophagus and esophago-gastric junction. *J Thorac Cardiovasc Surg* 2007; 134: 1284-91.
102. Power C, Byrne PJ, Lim K, Ravi N, Moore J, Fitzgerald T, Keeling PN, **Reynolds JV**. Superiority of anti-reflux stent compared with conventional stents in the management of patients with cancer of the lower oesophagus and esophago-gastric junction: results of a randomised clinical trial. *Dis Esophagus* 2007; 20: 466-70.
103. Ryan AM, Healy LA, Power DG, Rowley SP, **Reynolds JV**. Short-term nutritional implications of total gastrectomy for malignant disease with parenteral nutrition. *Clin Nutr* 2007; 26: 718-27.
104. Pidgeon GP, Lysaght J, Krishmanaoorthy S, **Reynolds JV**, O'Byrne K, Nie D, Honn KV. Lipoxgenase metabolism: roles in tumour progression and survival. *Cancer Metastasis Rev* 2007; 26: 718-27.
105. Ravi N, Al-Sarraf N, Balfe P, Byrne PJ, **Reynolds JV**. On-table endoscopy following laparoscopic fundoplication. *J Gastrointest Surg* 2007; PMID 17874274.
106. Ryan AM, Hearty A, Pritchard RS, Cunningham A, Rowley SP, **Reynolds JV**. Association of hypoalbuminemia on the first postoperative days and outcome following esophagectomy. *J Gastrointest Surg* 2007; 11: 1355-60.

ORIGINAL MANUSCRIPTS

107. Murphy JO, Ravi N, Byrne PJ, Mc Donald GS, **Reynolds JV**. Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux. *J Surg Res* 2007; 142: 20-7.
108. Butt J, Rowley S, Byrne PJ, **Reynolds JV**. Management of gastrointestinal stromal tumours: a single-centre experience. *Ir J Med Science* 2007; 176: 157-60.
109. Azim K, Mc Manus R, Brophy K, Ryan A, Kelleher D, **Reynolds JV**. Genetic polymorphisms and the risk of infection following esophagectomy: association with TNF-alpha -308 genotype. *Ann Surg* 2007; 246: 122-8.
110. Walshe L, Rowley S, Coffey M, Hollywood D, Kennedy MJ, Gillham C, Ravi N, **Reynolds JV**. Comparison of two fractionation regimens in the multimodal therapy of esophageal cancer. *Dis Esophagus* 2007; 20: 217-24
111. Byrne PJ, Ravi N, Al-Sarraf N, Rowley S, Moran T, **Reynolds JV**. The Rossetti-Nissen fundoplication – effective in managing gastro-esophageal reflux disease. *Surgeon* 2008; 6: 19-24.
112. Geraghty M, Draman M, Moran D, Muldoon C, **Reynolds JV**, Cullen MJ. Hypoglycaemia in an adult male: a surprising finding in pursuit of insulinoma. *Surgeon* 2008; 6: 57-60.
113. McGuill MJ, Byrne P, Ravi N, **Reynolds J**. The prognostic impact of occult lymph node metastasis in cancer of the esophagus or esophagogastric junction: systematic review and meta-analysis. *Dis Esophagus* 2008; 21: 236-40.
114. de Blacam C, Gray J, Boyle T, Kennedy MJ, Hollywood D, Butt J, Griffin M, Nicholson S, Dunne B, Wilson G, McDermott R, Murphy P, Short I, Rowley S, Connolly E, **Reynolds JV**. Breast cancer outcomes following a national initiative in Ireland to restructure delivery of services for symptomatic disease. *Breast* 2008; 17: 412-7.
115. Donnelly M, Anderson LA, Johnston BT, Watson RG, Murphy SJ, Comber H, Mc Guigan J, **Reynolds JV**, Murray LJ. Oesophageal cancer: caregiver mental health and strain. *Psychooncology*. 2008 ; 17: 1196-201.
116. Healy LA, Ryan AM, Moore J, Rowley S, Ravi N, Byrne PJ, **Reynolds JV**. Health related quality of life assessment at presentation may predict complications and early relapse in patients with localized cancer of the esophagus. *Dis Esophagus*. 2008; 21: 522- 8.
117. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, McGuigan J, **Reynolds JV**, Hardie LJ. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's cancer relationship case control study. *Cancer Epidemiol Biomarkers Prev*. 2008; 17: 736-9.

ORIGINAL MANUSCRIPTS

118. Ferguson HR, Wild CP, Anderson LA, Murphy SJ, Johnston BT, Murray LJ, Watson RG, Mc Guigan J, **Reynolds JV**, Hardie LJ. Cyclo-oxygenase and inducible nitric oxide synthase gene polymorphisms and risk of reflux oesophagitis, Barrett's esophagus, and esophageal adenocarcinoma. *Cancer Epidemiol Biomarkers Prev*. 2008; 17: 727-31.
119. Balfe P, **Reynolds JV**. A rare cause of acute abdomen- Plasmodium falciparum leading to splenic infarction and haemorrhage. *Irish Medical Journal*, 2008; 101: 150-1.
120. Ryan AM, Healy LA, Power DG, Byrne M, Murphy S, Byrne P, Kelleher D, **Reynolds JV**. Barrett's Esophagus: Prevalence of central adiposity, metabolic syndrome and a pro- inflammatory state. *Ann Surg* 2008; 247: 909-15.
121. Mulholland HG, Cantwell MM, Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Mc Guigan J, **Reynolds JV**, Comber H, Murray LJ. Glycaemic index, carbohydrate and fibre intakes and risk of reflux esophagitis, Barrett's esophagus and esophageal adenocarcinoma. *Cancer Causes Control* 2008 (18839322).
122. Abdel-Latif MM, Kelleher D, **Reynolds JV**. Potential role of NF-k-B in Esophageal Adenocarcinoma as an emerging Molecular Target., *J Surg Res* 2009 May ; 153(1) 172-80.
123. Balfe P, O'Briain S, Daly PA, **Reynolds JV**. Management of gastric lymphoma. *Surgeon* 2008; 6: 262-5.
124. Murphy TJ, Ravi N, **Reynolds JV**. Treatment options for esophageal cancer. *Expert Opinion Pharmacotherapy* 2008; 39: 3197-210.
125. Murphy TJ, Ravi N, **Reynolds JV**. New developments in oesophageal adenocarcinoma treatment. *European Oncology*. 2008; 4: 23-26.
126. Lynam-Lennon N, Maher SG, **Reynolds JV**. The roles of microRNA in cancer and apoptosis. *Biol Rev Camb Philos Soc* 2009; 84: 55-71.
127. Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Ferguson HR, Mc Guigan J, Comber H, **Reynolds JV**, Murray LJ. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. *Gastroenterology* 2009; 136: 799-805.
128. Babar M, Ennis D, Abdel-Laetif M, Byrne PJ, Ravi N, **Reynolds JV**. Differential molecular changes in patients with asymptomatic Barrett's esophagus treated by antireflux surgery or medical therapy. *Am J Surg* 2009;
129. Ryan AM, **Reynolds JV**, Healy L, Byrne M, Moore J, Brannelly N, Mc High A, Mc Cormack D, Flood P. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blind randomized controlled trial. *Ann Surg* 2009; 249: 355-63.

ORIGINAL MANUSCRIPTS

130. Pritchard D, Zaheer A, Ravi N, **Reynolds J**, Mahmud N. A “stitch in time”. *Gut* 2009; 58: 1341.
131. Mc Mahon MA, O’Kelly F, Lim KT, Ravi N, **Reynolds JV**. Endoscopic T-tube placement in the management of lye-induced esophageal perforation: Case report of a safe treatment strategy. *Patient Safety in Surgery* 2009; 3(1): 19.
132. Beddy P, Mc Grath A, **Reynolds JV**, Ryan JM. Primary embolisation of a symptomatic gastrointestinal stromal tumour. *J Vac Interv Radiol* 2009; 20: 1099-01.
133. McDowell DT, Smith FM, **Reynolds JV**, Maher SG, et al. Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. *Int J Colorectal Dis* 2009; 24(9): 1062-3.
134. Ennis DP, Pidgeon GP, Millar N, Ravi N, **Reynolds JV**. Building a bioresource for esophageal research: lessons from the early experience of an academic medical centre. *Dis Esophagus* 2009.
135. Abdel-Laetif MM, Duggan S, **Reynolds JV**, Kelleher D. Inflammation and esophageal carcinogenesis. *Curr Opin Pharmacol* 2009; 9: 396-404.
136. Howards JM, Hanly AM, Keogan M, Ryan M, **Reynolds JV**. Percutaneous cholecystomy- a safe option in the management of acute biliary sepsis in the elderly. *Int J Surg* 2009; 7: 94-9.
137. Jayaprakash N, O’Kelly F, Lim KT, Ravi N, **Reynolds JV**. Management of synchronous adenocarcinoma of the esophago-gastric junction and ampulla of Vater: case report of a surgically challenging condition. *Pat Safety Surg* 2009; 28: 3: 23.
138. O’Kelly F, Lim KT, Cooke F, Ravi N, **Reynolds JV**. An unusual presentation of Boerhaave syndrome. *Cases J* 2009; 2: 8000.
139. Feeney C, Hussey J, Carey M, **Reynolds JV**. Assessment of physical fitness for esophageal surgery, and targeting interventions to optimise outcomes. *Dis Esophagus* 2010 (20459443).
140. Healy LA, Ryan AM, Pidgeon G, Ravi N, **Reynolds JV**. Lack of differential pattern in central adiposity and metabolic syndrome in Barrett’s esophagus and gastro-esophageal reflux disease. *Dis Esophagus* 2010 23: 386-91.
141. Howard JM, Mongan AM, Manning BJ, Byrne P, Lawler P, Ravi N, **Reynolds JV**. Outcomes in achalasia from a surgical unit where pneumatic dilatation is first line therapy *Dis Esophagus* 2010 Aug;23(6):465-72.
142. Donohue CL, Pidgeon GP, Lysaght J, **Reynolds JV**. Obesity and gastrointestinal cancer. *Br J Surg* 2010; 97: 68-72.

ORIGINAL MANUSCRIPTS

143. Healy LA, Ryan AM, Carroll P, Ennis D, **Reynolds JV**. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. *Clin Oncol* 2010; 22:281-8.
144. O’Kelly F, Lim KT, Ravi N, Mahmud N, **Reynolds JV**. The value of double balloon enteroscopy in diagnosing blue rubber bleb naevus syndrome: a case report. *Case J*. 2010; 18: 29.
145. Howard JM, Pidgeon GP, **Reynolds JV**. Leptin and gastrointestinal malignancies *Obes Rev* 2010 (20149119).
146. Babar M, Addel –Laetif MM, Ravi N, Byrne PJ, Kelleher D, **Reynolds JV**. Pilot translational study of dietary vitamin C supplementation in Barrett’s oesophagus. *Dis Esophagus* 2010; 23: 271-6.
147. Byrne M, **Reynolds JV**, O’Donnell JS, et al. Long term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. *Br J Cancer* 2010; 102: 73-9.
148. Doyle SL, Lysaght J, **Reynolds JV**. Obesity and postoperative complications in patients undergoing non-bariatric surgery. *Obes Rev* 2009.
149. Martin-Smith JD, Larkin JO, Ravi N, **Reynolds JV**. Management of gastro-bronchial fistula complicating a subtotal esophagectomy: a case report. *BMC Surg* 2009; 24: 9: 20.
150. Power DG, **Reynolds JV**. Localized adenocarcinoma of the esophago-gastric junction – is there a standard of care? *Cancer Treat Rev* 2010; 36: 400-9.
151. Cathcart MC, **Reynolds JV**, O’Byrne KJ, Pidgeon GP. The role of prostacyclin synthase and thromboxane synthase signalling in the development and progression of cancer. *Biochem Biophys Acta* 2010; 1805: 153-6
152. Duggan SP, Behan FM, Kirca M, Smith S, **Reynolds JV**, Long A, Kelleher D. An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid response gene, downregulated in Barrett’s oesophagus, which regulates NF-kappa B activation and cytokine levels. *Carcinogenesis* 2010; 31: 936-45
153. Donohue CI, **Reynolds JV**. Short Bowel Syndrome. *Surgeon* 2010; 8: 270-9.
154. Murphy SJ, Anderson LA, Ferguson HR, **Reynolds JV**, et al. Dietary antioxidant and mineral intake in humans is associated with reduced risk of esophageal adenocarcinoma but not reflux esophagitis or Barrett’s esophagus. *J Nutr* 2010.140: 1753-68
155. **Reynolds JV**, Murphy TJ, Ravi N. Multimodality therapy for adenocarcinoma of the esophagus, gastric cardia and upper gastric third. *Recent Results Cancer Res* 2010; 97: 1028-34.

ORIGINAL MANUSCRIPTS

156. Beddy P, Howard J, Mc Mahon C, Knox M, de Blacam C, Ravi N, Pidgeon GP, **Reynolds JV**. Association of visceral obesity with oesophageal and junctional adenocarcinoma. *Br J Surg* 2010; 97: 1028-34.
157. Howard JM, Beddy P, Ennis D, Keogan M, Pidgeon GP, **Reynolds JV**. Associations between leptin and adiponectin receptor upregulation, visceral adiposity and tumour stage in oesophageal and junctional adenocarcinoma. *Br J Surg* 2010; 97: 1020-7.
158. Healy LA, Ryan AM, **Reynolds JV**, et al. Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. *Int J Colorectal Dis* 2010, in press
159. Lynham-Lennon N, **Reynolds JV**, Pidgeon GP, Lysaght J, Marignol L, Maher SG. Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma. *Radiat Res* 2010, 174: 703-11
160. **Reynolds JV**, Ravi N, Muldoon C, Larkin JO, Rowley S, O'Byrne K, Hollywood D, O'Toole D. Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. *World J Surg* 2010 .34: 2821-9
161. Malik V, Lucey JA, Duffy GJ, **Reynolds JV**. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. *J Nucl Med* 2010; 51: 1863-9.
162. Howards JM, Ryan L, Lim KT, **Reynolds JV**. Oesophagectomy in the management of end-stage achalasia- Case reports and review of the literature. *Int J Surg* 2011; 9: 204-8.
163. **Reynolds JV**, Donohoe CL, Doyle SL. Diet, obesity and cancer. *Ir J Med Sci* 2011, 180: 521-7
164. Loh JK, O'Kelly F, Lim KT, Shields W, Ravi R, Keeling PN, **Reynolds JV**. Triple vessel mesenteric ischaemia presenting with gastric ulceration. *Ir J Med Sci* 2011, 180: 537-40
165. Larkin JO, Moriarity AR, O'Mahony Dm Meaney J, **Reynolds JV**. Gallstone ileus in evolution. *ANZ J Surg* 2011; 81: 287-8
166. Philbin DM, Larkin JO, Ravi N, Wilson G, **Reynolds JV**. Recurrent melaena in a 21-year old female. *ANZ J Surg* 2011; 81: 181-2
167. Feeney C, **Reynolds JV**, Hussey J. Preoperative physical activity levels and postoperative pulmonary complications post-esophagectomy. *Dis Esophagus* 2011, 24: 489-94
168. Pazko E, Ehrhardt C, Senge MO, Kellheher DP, **Reynolds JV**. Nanodrug applications in photodynamic therapy. *Photodiagnosis Photodyn therapy*. 2011; 8: 14-9

ORIGINAL MANUSCRIPTS

169. Donohoe CL, Nguyen M, Cook J **Reynolds JV**. Fast track protocols in colorectal surgery. *Surgeon* 2011; 9: 95-103
170. Donohoe CL, Macgillcuddy E, **Reynolds JV**. The impact of young age on outcomes in esophageal and junctional cancer. *Dis Esophagus* 2011, 24 (8): 560-8.
171. Ryan AM, Duong M, Healy L, Ryan SA, Parekh SA, **Reynolds JV**, Power DG. Obesity, metabolic syndrome and esophageal adenocarcinoma: Epidemiology, etiology and new targets. *Cancer Epidemiol* 2011; 35:309-19
172. Lysaght J, Allot EH, Donohoe CL, Howard JM, Pidgeon GP, **Reynolds JV**. T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. *Br J Surg* 2011; 98(7):964-74.
173. Donohoe CL, McGillycuddy E, **Reynolds JV**. Long-term health related quality of life for disease-free esophageal cancer patients. *World J Surg* 2011; 35: 1853-60
174. Carroll PA, Healy L, Lysaght J, Boyle T, **Reynolds JV**, et al. Influence of the metabolic syndrome on leptin and leptin receptor in breast cancer. *Mol Carcinogenesis* 2011; 50: 643-51.
175. Healy L, Howard J, Ryan A, Beddy P, Mehigan B, **Reynolds JV**. Metabolic syndrome and leptin are associated with adverse pathologic features in male colorectal cancer patients. *Colorectal Dis* 2011; 10: 1463-8.
176. Donohoe CL, Doyle SL, **Reynolds JV**. Visceral adiposity, insulin resistance and cancer risk. *Diabetol Metab Syndrom* 2011; 22: 3: 12-18.
177. Mulholland HG, Murray LJ, Anderson LA, **Reynolds JV**, et al. Vitamin D, calcium and dietary intake, and risk of oesophageal adenocarcinoma and its precursor conditions. *Br J Nutr* 2011; 106: 732-41.
178. Donohoe CL, Ryan AM, **Reynolds JV**. Cancer cachexia: mechanisms and clinical implications. *Gastroenterol Res pract* 2011: 601434.
179. Maher SG, **Reynolds JV**. Basic concepts of inflammation and its role in carcinomgenesis. *Recent Results Cancer Res* 2011; 185: 1-34.
180. Larkin JO, Cooke F, Ravi N, **Reynolds JV**. Internal hernia following total gastrectomy with Roux-en-Y reconstruction. *Ann Royal Coll Surg Engl* 2011; 93: 71-3.
181. Lysaght J, van der Stok EP, Allot EH **Reynolds JV**. Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. *Cancer Lett*; 2011; 312: 62-72.
182. Donohoe Cl, O'Farrell NJ, Ravi N, **Reynolds JV**. Evidence-based selective application of transhiatal esophagectomy in a high-volume esophageal center. *World J Surg* 2012 Jan 36 (1): 98-103.

ORIGINAL MANUSCRIPTS

183. **Reynolds JV**, Donohoe CL, Ravi N, O'Byrne K, Hollywood D. Modern operative and oncological outcome in oesophageal cancer. *Ir Med J* 2011. 104(8): 235-8.
184. **Reynolds JV**, Donohoe CL, McGillicuddy E, Ravi N, O'Toole D, O'Byrne K, Hollywood D. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: Lessons from the experience of a high-volume esophageal center. *J Thoracic Cardiovasc Surg* 2012; 143(5):1130-1137.
185. Maher SG, Mc Dowell DT, Collins B, **Reynolds JV**. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal response to neoadjuvant chemoradiation. *Ann Surg* 2011; 254: 809-16.
186. Cathcart MC, O'Byrne KJ, **Reynolds JV**. COX-derived prostanoid pathways in gastrointestinal cancer development: novel targets for intervention. *Biochem Biophys Acta* 2011; 1825: 49-63.
187. Mc Ardle A, Conneely JB, Ravi N, **Reynolds JV**. Duodenal duplication cyst presenting with gastric outlet obstruction in an adult male. *Endoscopy*. 2011; 43: e352-3.
188. Naidoo J, O'Toole T, Kennedy MJ, **Reynolds JV** A single institution experience of streptozotocin/fluorouracil combination chemotherapy: a case series. *Irish J Med Sci* 2012 Jun 181(2):211-4.
189. Donohoe CL, Feerney C, Carey MF, **Reynolds JV**. Perioperative evaluation of the obese patients. *J Clin Anaest* 2011; 23: 575-86.
190. Doyle SL, Donohoe CL, Lysaght J, **Reynolds JV**. Visceral obesity, metabolic syndrome, insulin resistance and cancer. *Proc Nutr Soc* 2011; 3: 1-9.
191. Allott EH, Lysaght J, Cathcart MC, Donohoe CL, Cummins R, McGarrigle SA, Kay E, **Reynolds JV**, Pidgeon GP. MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation. *Mol Carcinog*. 2011 Nov 28.
192. Doyle SL, Donohoe CL, Finn SP **Reynolds JV**, Lysaght J. IGF-1 and its receptor in esophageal cancer: association with adenocarcinoma and visceral obesity. *Am J Gastroenterol*. 2012 Feb;107(2):196-204.
193. Hötte GJ, Linam-Lennon N, **Reynolds JV**, Maher SG. Radiation sensitivity of esophageal adenocarcinoma: the contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance. *Radiat Res*. 2012 Mar;177(3):272-9.
194. Lahiff C, Shields W, Cretu I, Mahmud N, McKiernan S, Norris S, Silke B, **Reynolds JV**, O'Toole D. Upper gastrointestinal bleeding: predictors of risk in a mixed patient group including variceal and nonvariceal haemorrhage. *Eur J Gastroenterol Hepatol*. 2012 Feb;24(2):149-54.

ORIGINAL MANUSCRIPTS

195. Martin-Smith JD, Larkin JO, Hogan JG, Ravi N, **Reynolds JV**. Necrotizing pancreatitis presenting with pneumatosis coli and hepatic portal venous gas. *ANZ J Surg*. 2011 Jun;81(6):467-8.
196. Mc Cormack O, Timlin M, Mc Gowan A, Healy ML, Ravi N, **Reynolds JV**. Management of squamous cell cancer of the oesophagus in a patient with a polyglandular endocrinopathy (APECED) and achalasia. *J Gastrointest Surg*. 2012 Oct;16(10):1963-6.
197. O'Kelly F, Lim KT, Hayes B, Shields W, Ravi N, **Reynolds JV**. The Houdini effect--an unusual case of blunt abdominal trauma resulting in perforative appendicitis. *Ir Med J*. 2012 Mar;105(3):86-7.
198. Donohoe CL, **Reynolds JV**. Defining a Successful Esophagectomy. *Ann Surg*. 2012 May 10.
199. Costelloe J, Mc Cormack O, **Reynolds JV**. Dissecting intramural hematoma of the esophagus. *Dis Esophagus*. 2012 May 29.
200. Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, Murray LJ, Murphy SJ, Johnston BT, Comber H, **Reynolds JV**, McManus R. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. *Am J Gastroenterol*. 2012 Sep;107(9):1331-41.
201. Mc Cormack O, Meaney JF, **Reynolds JV**. Resolving sclerosing mesenteritis. *Surgery*. 2012 Jun 7.
202. Lynam-Lennon N, **Reynolds JV**, Marignol L, Sheils OM, Pidgeon GP, Maher SG. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. *J Mol Med (Berl)*. 2012 Dec;90(12):1449-58.
203. Costelloe J, O'Connell C, Mc Cormack O, Maccarthy F, Halpenny DF, Shatwan R, Muldoon C, Ravi N, **Reynolds JV**. Malignant Gastrocolic Fistula as a Late Complication of Radiation Therapy. *J Gastrointest Cancer*. 2012 Jun 21.
204. Allott EH, Oliver E, Lysaght J, Gray SG, **Reynolds JV**, Roche HM, Pidgeon GP. The SGBS cell strain as a model for the in vitro study of obesity and cancer. *Clin Transl Oncol*. 2012 Oct;14(10):774-82.
205. Picardo SL, Maher SG, O'Sullivan JN, **Reynolds JV**. Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. *Dig Surg*. 2012;29(3):251-60.
206. Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC **Reynolds JV**, Kelleher DP et al. Esophageal Adenocarcinoma Genetics Consortium; Wellcome Trust Case Control Consortium 2. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. *Nat Genet*. 2012 Oct;44(10):1131-6.

ORIGINAL MANUSCRIPTS

207. Crosby DA, Donohoe CL, Fitzgerald L, Muldoon C, Hayes B, O'Toole D, **Reynolds JV**. Gastric neuroendocrine tumours. *Dig Surg*. 2012;29(4):331-48.
208. Malik V, Johnston C, Donohoe C, Claxton Z, Lucey J, Ravi N, **Reynolds JV**. (18)F-FDG PET-detected synchronous primary neoplasms in the staging of esophageal cancer: incidence, cost, and impact on management. *Clin Nucl Med*. 2012 Dec;37(12):1152-8.
209. Allott EH, Morine MJ, Lysaght J, McGarrigle SA, Donohoe CL, **Reynolds JV**, Roche HM, Pidgeon GP. Elevated Tumor Expression of PAI-1 and SNAI2 in Obese Esophageal Adenocarcinoma Patients and Impact on Prognosis. *Clin Transl Gastroenterol*. 2012 Apr 19;3:e12.
210. O'Farrell NJ, **Reynolds JV**, Ravi N, Larkin JO, Malik V, Wilson GF, Muldoon C, O'Toole D. Evolving changes in the management of early oesophageal adenocarcinoma in a tertiary centre. *Ir J Med Sci*. 2012 Dec 16
211. Mc Cormack O, Cooney JM, Doherty CP, Muldoon C, **Reynolds JV**. Paraneoplastic limbic encephalitis from esophagogastric squamous cell carcinoma successfully managed by radical gastrectomy. *Surgery*. 2013 Jan 7.
212. O'Farrell NJ, Donohoe CL, Muldoon C, Costelloe JM, King S, Ravi N, **Reynolds JV**. Lack of Independent Significance of a Close (<1mm) Circumferential Resection Margin Involvement in Esophageal and Junctional Cancer. *Ann Surg Oncol*. 2013 Mar 6.
213. Martin-Smith JD, Larkin JO, Ravi N, **Reynolds JV**. Severe epigastric pain following a birthday party. *Ir Med J*. 2013 Jan;106(1):23.
214. Doyle SL, Bennett AM, Donohoe CL, Mongan AM, Howard JM, Lithander FE, Pidgeon GP, **Reynolds JV**, Lysaght J. Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research. *Nutr Res*. 2013 Mar;33